Publications & Posters
TL-532, a novel rationally designed TLR3 agonist, induces tumor-specific apoptosis, immune simulation, life-long anti-tumor auto-vaccination, and reverses resistance to immune checkpoint inhibitors
OTS – October 2022, Phoenix (USA) – M Bonnin
TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
IRCI 15-17 June 2022 Lyon – M Bonnin
TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
AACR 8-13 Avril 2022 New Orleans – S Thierry
Synthetic TLR-3 ligands
ESMO – December 2021 – Presented by Dr Bettina Werle
Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule
OTS – September 2021 – Dr Marc Bonnin
First Rationally Designed TLR3 Agonist “TL-532”Induces Tumor Specific Apoptosis, Microenvironment Switch and Immune Stimulation, Leading to Life-long Anti-tumor Auto-vaccination
OTS – September 2021 – Dr Sylvain Thierry
First rationally designed Toll-like Receptor 3 agonist “TL-532”induces apoptosis specific of tumor cells and long-lasting anti-tumor Immunity
EACR – June 2021 – Dr Sylvain Thierry
Discovery process and in vitrobiological characterization of rationally designed TL-532 Toll-like Receptor 3 (TLR3) agonist as anti-cancer molecule
EACR – June 2021 – Dr Marc Bonnin
TL-532, the first rationally designed TLR3 agonist creates long-lasting tumor specific immunity in vivo
Sting & TLR-targeted therapies – May 2021 – Presented by Dr Bettina Werle
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma
Vanbervliet-Defrance B, Delaunay T, Daunizeau T, Kepenekian V, Glehen O, Weber K, Estornes Y, Ziverec A, Djemal L, Delphin M, Lantuéjoul S, Passot G, Grégoire M, Micheau O, Blanquart C, Renno T, Fonteneau JF, Lebecque S, Mahtouk K.
Cancer Lett. 2019 Dec 12. pii: S0304-3835(19)30622-6. doi: 10.1016/j.canlet.2019.12.016
Corrigendum to “Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis” [J Hepatol 71 (2019) 763-772]
2. Bonnin M, Fares N, Testoni B, Estornes Y, Weber K, Vanbervliet B, Lefrançois L, Garcia A, Kfoury A, Pez F, Coste I, Saintigny P, Viari A, Lang K, Guey B, Petrilli V, Hervieu V, Bancel B, Bartosch B, Durantel D, Renno T, Merle P, Lebecque S
J Hepatol. 2019 Nov 25. pii: S0168-8278(19)30651-8. doi: 10.1016/j.jhep.2019.11.001.
Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.
Alkurdi L, Virard F, Vanbervliet B, Weber K, Toscano F, Bonnin M, Le Stang N, Lantuejoul S, Micheau O, Renno T, Lebecque S, Estornes Y.
Cell Death Dis. 2018 Aug 29; 9(9):874
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
Hum Pathol. 2016 Jun;52:9-18.
Cleaved/associated TLR3 represents the primary form of the signaling receptor.
Toscano F, Estornes Y, Virard F, Garcia-Cattaneo A, Pierrot A, Vanbervliet B, Bonnin M, Ciancanelli MJ, Zhang SY, Funami K, Seya T, Matsumoto M, Pin JJ, Casanova JL, Renno T, Lebecque S.
J Immunol. 2013 Jan 15; 190(2):764-73.
dsRNA induces apoptosis through an atypical death complex associating TLR3 to caspase-8.
Estornes Y, Toscano F, Virard F, Jacquemin G, Pierrot A, Vanbervliet B, Bonnin M, Lalaoui N, Mercier-Gouy P, Pachéco Y, Salaun B, Renno T, Micheau O, Lebecque S.
Cell Death Differ. 2012 Sep;19(9):1482-94
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer.
Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, Massacrier C, Conforti R, Chenard MP, Sabourin JC, Goubar A, Lebecque S, Pierres M, Rimoldi D, Romero P, Andre F.
Cancer Res. 2011 Mar 1;71(5):1607-14. doi: 10.1158/0008-5472.CAN-10-3490. Epub 2011 Feb 22.
Toll-like receptors two-edged sword: when immunity meets apoptosis.
Salaun B, Romero P, Lebecque S.
Eur J Immunol. 2007 Dec;37(12):3311-8.
Toll-like receptor 3 expressed by melanoma cells as a target for therapy?
Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P.
Clin Cancer Res. 2007 Aug 1; 13(15 Pt 1):4565-74
TLR3 can directly trigger apoptosis in human cancer cells.
Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T.
J Immunol. 2006 Apr 15;176(8):4894-901.
Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.).
Lacour J, Laplanche A, Delozier T, Berlie J, Mourali N, Julien JP, De Gislain C, Namer M, Petit JC, Denis V, et al.
Breast Cancer Res Treat. 1991 Sep;19(1):15-21.
Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer.
Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, Sarrazin D, Contesso G, Viguier J.
Lancet. 1980 Jul 26;2(8187):161-4.

Tollys
Cutting-Edge Cancer Immunotherapy
Office
60F avenue Rockefeller
69008 Lyon, FRANCE